[Results of the 1st Austrian ovarian cancer study: prospective randomized comparison of a new sequential chemotherapy with 2 standard regimens in 150 stage III and IV patients].
The results of a randomized trial of 150 patients, who were either treated with 6 cycles of adriamycin (40 mg/m2) and cyclophosphamide (500 mg/m2) or a combination of adriamycin (40 mg/m2) and cis-platin (50 mg/m2) or a combination of a cross-over regime: adriamycin (40 mg/my day 1), cisplatin (100 mg/my day 2), vincristine (1.4 mg/m2 day 28), cyclophosphamide (1.500 mg/m2 day 25), methotrexate (1.000 mg/m2 day 56) (a total of 2 cycles) are summarized forthwith. The longest mean survival times were obtained in the cross-over regime (19.6 months). The patients with highly differentiated tumors benefited most from this type of chemotherapy: mean survival time 26.3 months as opposed to 17.6 months.